Improving Cancer Screening Efficiency: Advances in blood-based multi-cancer early detection
Approximately 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) each year. Utilization of guideline-recommended cancer screening paradigms allows for timely initiation of therapy and superior clinical outcomes for many of these patients. However, only four screening methodologies are guideline-recommended, and patient adherence to regular screening is suboptimal. Cancers responsible for 71% of cancer deaths have no recommended screening methodologies.
Technical advances in next-generation sequencing and machine learning algorithms have transformed our ability to detect cancer-derived cell-free DNA in the blood. Utilization of minimally-invasive blood-based assays that can detect and localize multiple cancers have the potential to dramatically improve the efficiency of cancer detection. This activity will provide an overview of trial data related to the development of a blood-based multi-cancer early detection test.
Target Audiences: Primary care physicians, internists, family practice physicians, and related healthcare professionals involved in the care of people who undergo screening for cancer.
Presenter: Monica Buchanan, PhD, is Regional Director of Medical Science Liaisons at GRAIL. Monica is driven by a vision of improving the lives of people with cancer through disruptive genetic technology. She comes to GRAIL with nearly a decade of medical affairs experience in the oncology divisions at Array BioPharma, Genentech, and Lilly. Prior to her industry career, Monica completed a postdoctoral fellowship at UPMC Hillman Cancer Center where she conducted oncology-related laboratory research. Monica holds a BS in biology from Emory University and a PhD in Molecular and Human Genetics from Baylor College of Medicine.
Three Outcomes – what participants will take away from attending the webinar
- Ability to discuss the need for early screening of various cancer types and the impact on improving patient survival.
- Confidence in a new paradigm for early cancer detection through the convergence of genomics and artificial intelligence/machine learning
- Ability to evaluate the sensitivity and specificity of blood tests for cancer detection.
This webinar is sponsored by: